PATENT CLAIM ANALYSIS

Application Number: 15752130
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "247000"]

Abstract:
The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide).

Claim (Index 16):
A kit for use in the method of  claim 1 , the kit comprising an effective amount of DNMDP, zardaverine, and/or anagrelide, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.44444
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12085023', '15101865', '15250402', '13980180', '14466668']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7403029336602639
- 35 USC 102 Novelty (BERT): 0.4892486654932915
- Combined Prediction Score: 0.7151975068435666
- Mean Citation Score: 191.70974
- Max Citation Score: 193.88573
- Similarity Product: 133.27845747646094

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test